• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Cochrane Review: Do Low-Carb Diets Improve Weight-Loss for Overweight and Obese Adults?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • There is much debate surrounding various diets for the management of adulthood obesity  
  • Naude et al. (Cochrane Database of Systematic Reviews, 2022) compared the effects of low-carbohydrate weight-reducing diets to weight-reducing diets with balanced ranges of carbohydrates in adults who are overweight or obese without and with type 2 diabetes mellitus (T2DM) 

METHODS: 

  • Systematic review and meta-analysis 
  • Study inclusion criteria 
    • RCTs 
    • Adults who are overweight or obese, with or without T2DM, and with or without cardiovascular conditions or risk factors 
    • Studies needed to  
      • Compare low-carb weight-reducing diets to balanced-carb (45% to 65% of total energy) weight-reducing diets 
      • Have a weight-reducing phase of at least 2 weeks or longer 
      • Be explicitly implemented for the primary purpose of reducing weight, with or without advice to restrict energy intake 
  • Study design 
    • Certainty of evidence was assessed using GRADE criteria  
    • Analyses were stratified by  
      • Participants with and without T2DM 
      • Diets with weight-reducing phases only and those with weight-reducing phases followed by weight-maintenance phases 
    • Primary outcomes were assessed at  
      • Short-term follow-up (3 to <12 months)  
      • Long-term follow-up (≥12 months)  
  • Primary outcomes 
    • Change in body weight (kg) 
    • Number of participants per group with weight loss of at least 5% 

RESULTS: 

  • 61 RCTs | 6925 total participants 
  • Included studies 
    • All studies were conducted in high-income countries, except for 1 in China 
    • Most investigated low-carb diets (> 50 g to 150 g per day or < 45% of total energy; n = 42) 
    • Quality of evidence was assessed as moderate to very low across outcomes 
  • Included trial participant characteristics 
    • Mean baseline weight: 95 (range 66 to 132) kg 
    • Participants with T2DM: 1807  
      • Participants with T2DM mean age: 57 (range 50 to 65) years 
      • Participants without T2DM mean age: 45 (range 22 to 62) years 
    • Most trials included people without baseline cardiovascular conditions, risk factors or events (36 trials out of 61) 
    • Mean baseline diastolic blood pressure (DBP) and low-density lipoprotein (LDL) cholesterol across trials were within normal ranges 
  • Participants both with and without T2DM lost weight when following weight reducing phases of both diets at  
    • Short-term follow-up: range 12.2 to 0.33 kg 
    • Long-term follow-up: range 13.2 to 1.7 kg 

Participants without T2DM 

  • Low-carb weight-reducing diets vs balanced-carbo weight-reducing diets, probably result in little to no difference in change in body weight  
    • Over three to 8.5 months 
      • Mean difference −1.07 kg, (95% CI, −1.55 to −0.59) 
      • 3286 participants, 37 RCTs; moderate-certainty evidence 
    • Over one to two years 
      • MD −0.93 kg (95% CI, −1.81 to −0.04) 
      • 1805 participants, 14 RCTs; moderate-certainty evidence 
  • There was also probably little to no difference in change in DBP and LDL cholesterol over one to two years 
  • The evidence is very uncertain about whether there is a difference in the number of participants per group with weight loss of at least 5% at one year 
    • Risk ratio (RR) 1.11 (95% CI, 0.94 to 1.31) 
    • 137 participants, 2 RCTs; very low-certainty evidence 

Participants with T2DM 

  • Low-carb weight-reducing diets compared to balanced-carb weight-reducing diets probably result in little to no difference in change in body weight 
    • Over three to six months 
      • MD −1.26 kg (95% CI; −2.44 to −0.09) 
      • 1114 participants, 14 RCTs; moderate-certainty evidence 
    • Over one to two years 
      • MD −0.33 kg (95% CI, −2.13 to 1.46) 
      • 813 participants, 7 RCTs; moderate-certainty evidence 
  • There was also probably little to no difference in change in DBP, HbA1c and LDL cholesterol over 1 to 2 years 
  • The evidence is very uncertain about whether there is a difference in the number of participants per group with weight loss of at least 5% at one to two years 
    • RR 0.90 (95% CI, 0.68 to 1.20) 
    • 106 participants, 2 RCTs; very low-certainty evidence 

Safety 

  • Evidence on participant-reported adverse effects was limited, so no conclusions are presented 

CONCLUSION: 

  • Low-carb weight-reducing diets are probably no better or worse at promoting weight loss in participants who are overweight or obese than are balanced-carb weight-reducing diets  
  • Type 2 diabetes status did not have a significant effect on diet type success 
  • The authors state

There is probably little to no difference in weight reduction and changes in cardiovascular risk factors up to two years’ follow-up, when overweight and obese participants without and with T2DM are randomised to either low-carbohydrate or balanced-carbohydrate weight-reducing diets 

Learn More – Primary Sources: 

Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Results from the TEMPO Diet Trial: What are the Long-term Effects of Severe Energy-Restriction for Women with Postmenopausal Obesity?
RCT Results: Can Liraglutide Therapy Improve Weight Loss Maintenance for Adults with Obesity?
Is the DASH Diet Effective for Obese Women with PCOS?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site